|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM257539522 |
| 003 |
DE-627 |
| 005 |
20250219174339.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2016.02.004
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0858.xml
|
| 035 |
|
|
|a (DE-627)NLM257539522
|
| 035 |
|
|
|a (NLM)26883681
|
| 035 |
|
|
|a (PII)S1521-6616(16)30020-1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Vadasz, Zahava
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.07.2016
|
| 500 |
|
|
|a Date Revised 07.03.2016
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2016 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a INTRODUCTION: B cell receptor (BCR) -mediated signals are enhanced when CD72 expression is deficient on B cells in autoimmune diseases. The significance of soluble CD72 (sCD72) has not been elucidated
|
| 520 |
|
|
|a METHODS: Soluble CD72 was analyzed in the serum of 159 SLE patients, 40 rheumatoid arthritis (RA) patients, and 100 healthy individuals. Correlations between sCD72 and SLE disease activity (SLEDAI) were assessed
|
| 520 |
|
|
|a RESULTS: Soluble CD72 was found increased in SLE patients, when compared to both RA patients and healthy individuals (20.2 ± 1.2 ng/ml; 10.6 ± 4.6 ng/ml and 7.2 ± 3.3 ng/ml; p < 0.001). Soluble CD72 level was significantly higher in SLE patients with renal involvement than in patients without (31.8 ± 2.3 ng/ml vs 13.9 ± 0.9 ng/ml; p < 0.001) and also with the presence of auto-antibodies
|
| 520 |
|
|
|a CONCLUSION: Soluble CD72 is significantly increased in SLE patients mainly in those with renal involvement. Increased sCD72 may become a potential biomarker for renal involvement in SLE
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Nephritis
|
| 650 |
|
4 |
|a SLE
|
| 650 |
|
4 |
|a SLEDAI
|
| 650 |
|
4 |
|a Soluble CD72
|
| 650 |
|
4 |
|a anti-cardiolipin antibody
|
| 650 |
|
4 |
|a anti-dsDNA antibody
|
| 650 |
|
7 |
|a Antibodies, Antinuclear
|2 NLM
|
| 650 |
|
7 |
|a Antigens, CD
|2 NLM
|
| 650 |
|
7 |
|a Antigens, Differentiation, B-Lymphocyte
|2 NLM
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a CD100 antigen
|2 NLM
|
| 650 |
|
7 |
|a CD72 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Semaphorins
|2 NLM
|
| 700 |
1 |
|
|a Goldeberg, Yair
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Halasz, Katty
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rosner, Itzhak
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Valesini, Guido
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Conti, Fabrizio
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Perricone, Carlo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sthoeger, Zev
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bezalel, Shira Rosenberg
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tzioufas, Athanasios G
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Levin, Nancy Agmon
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shoenfeld, Yehuda
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Toubi, Elias
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 164(2016) vom: 04. März, Seite 114-8
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:164
|g year:2016
|g day:04
|g month:03
|g pages:114-8
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2016.02.004
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 164
|j 2016
|b 04
|c 03
|h 114-8
|